ArticleArchives of Razi Institute2025
Screening of Biofilm-Producing Genes from
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Manufacturing Technology and Effectiveness of Corona Vaccines: A Bibliometric Review.Archives of Razi Institute · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter, recognized as a nosocomial pathogen, undergoes structural changes when exposed to various antibiotics, rendering it relatively resistant and posing challenges in disease treatment. This study aimed to identify two biofilm-related genes and assess the drug resistance profile of clinical strains. Clinical isolates were collected from the ICU of Afzalipour Hospital in Kerman, Iran, and phenotypically identified. Confirmation was achieved for 55 clinical Acinetobacter isolates. Antibiogram testing was conducted for meropenem, amikacin, ampicillin-sulbactam, cefotaxime, levofloxacin, rifampin, and tigecycline antibiotics. Biofilm formation ability was assessed using microtiter plates and crystal violet staining, followed by spectrophotometry at OD 490 nm. PCR was employed to determine the frequency of pslA and pelB genes. Analysis revealed that the highest age group affected was 1 to 15 years (19%), while the lowest was 26 to 35 years (5%). The frequencies of pslA and pelB genes were 34.5% and 65.5%, respectively, and drug resistance ranged from 72% to 100% for the mentioned antibiotics. Given the pelB gene's approximately twofold higher frequency compared to pslA, it suggests that in most studied isolates, Psl may often be disrupted or that intracellular c-di-GMP levels have significantly increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.